anti-Complement Factor C9, mAb (64E9)

CHF 322.00
In stock
YIF-LF-MA0168100 µlCHF 322.00
More Information
Product Details
Synonyms C9
Product Type Monoclonal Antibody
Clone 64E9
Isotype Mouse IgG1 κ
Immunogen/Antigen Protein purified from human plasma.
Application Western Blot (1:2,000)
Crossreactivity Human
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Product Specification Sheet
Datasheet Download PDF
Complement factor C9, 71kDa, is the last of the human complement components creating the membrane attack complex (MAC). Activation of the complement system leads to the formation of the MAC, which in turn causes lysis, and death of target cells. C9 plays an important role in inflammatory reactions since it is essential for lytic action of the MAC. Such lytic action could be the basis for complement autotoxicity. Like most of the complement components, C9 belongs to the acute-phase proteins which are generally of hepatic origin, and their plasma concentrations increase (or decrease) following tissue injury and inflammation. Also, because C9 is required for the MAC of complement to become functional, interfering with signaling pathways that stimulate its production could offer new therapeutic strategies for treating various neurodegenerative disorders. Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.
Product References
1) Stanley KK. Curr Top Microbiol Immunol. (1989) vol.140: pp.49-65. (General)
2) Klegeris A, et al, Exp Gerontol. (2001) vol.36(7): pp.1179-88. (General)
3) Witzel-Schlomp K, et al, Eur J Immunogenet. (2001) vol.28(5): pp.515-22. (General)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.